We are a biopharmaceutical company in the late stages of clinical development, committed to the exploration, advancement, and marketing of cutting-edge treatments harnessing the physiological attributes of human perinatal tissues and cells. Our primary focus is on enhancing the quality of life for patients and addressing their unsatisfied medical requirements. Our primary product, Signature Cord Prime™, is specifically tailored to alleviate the effects of osteoarthritis in the knee. Furthermore, Arugula is dedicated to the formulation and distribution of innovative therapies for the treatment of chronic inflammatory and degenerative conditions.